SCHEMBL409541

SCHEMBL409541

Cc1ccc(C(=N)NO)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
ALDH1A1 P00352 6/20 0.44
GAA P10253 1/20 0.44
CES2 O00748 3/20 0.44
CES1 P23141 3/20 0.44
LMNA P02545 2/20 0.44
TDP1 Q9NUW8 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
ACHE P22303 2/20 0.40
PKM P14618 2/20 0.39
HTT P42858 2/20 0.39
ATM Q13315 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 1/20 0.39
NLRP1 Q9C000 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12348299 0.87 HSD17B10 (0.36) HDAC1HDAC6ALDH1A1LMNAHPGD
SCHEMBL6509390 0.84 ALDH1A1 (0.57) HDAC1HDAC6ALDH1A1ACHEPKM
SCHEMBL8213052 0.80 ALDH1A1 (0.44) HDAC1HDAC6ALDH1A1GAACES2
SCHEMBL2950699 0.78 ALDH1A1 (0.43) HDAC1HDAC6ALDH1A1GAACES2
SCHEMBL566487 0.77 CES2 (0.46) HDAC1HDAC6CES2CES1LMNA
SCHEMBL771387 0.77 LMNA (0.50) ALDH1A1GAALMNASMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL4394978 0.76 ALDH1A1 (0.41) HDAC1HDAC6ALDH1A1GAACES2
SCHEMBL21424948 0.76 NPC1 (0.57) ALDH1A1TDP1SMN1; SMN2NPC1RAB9A
SCHEMBL20090530 0.76 APP (0.42) HDAC1HDAC6ALDH1A1HPGDMAPT
SCHEMBL5900818 0.75 PRMT5 (0.30) ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291183-B1 OXADIAZOLYL DIHYDROPYRANO[2,3-B]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS ICAHN SCHOOL MED MOUNT SINAI (US) 2026-04-08 EP disclosed
US-12486240-B2 Oxadiazole compounds for controlling or preventing phytopathogenic fungi PI INDUSTRIES LTD. (IN) 2025-12-02 US disclosed
US-20250179084-A1 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2025-06-05 US disclosed
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 US disclosed
US-20240400546-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-12-05 US disclosed
US-20240300938-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 US disclosed
US-11970486-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-30 US disclosed
US-20240124435-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-04-18 US disclosed
WO-2024068520-A1 3-(HETERO)ARYL-5-CHLORODIFLUOROMETHYL-1,2,4-OXADIAZOLE AS FUNGICIDE BAYER AKTIENGESELLSCHAFT (DE) 2024-04-04 WO disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
US-20050113400-A1 Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo SHUNICHI SHIOZAWA (JP) 2005-05-26 US disclosed
CN-1568187-A 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof ICOS CORP (US) 2005-01-19 CN disclosed
EP-1445249-A1 NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-08-11 EP disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed
US-6150352-A ARYLQUINOLONE ANALOGS MERCK & CO., INC. (US) 2000-11-21 US disclosed
EP-0901489-A1 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE Merck & Co., Inc. (US) 1999-03-17 EP disclosed
WO-1997044339-A1 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE MERCK & CO., INC. (US) 1997-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124435-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 HDAC1 1659/4885HDAC6 50/4885ALDH1A1 656/4885
US-20240300938-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 HDAC1 1659/4885HDAC6 50/4885ALDH1A1 656/4885
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 HDAC1 19/4885HDAC6 33/4885ALDH1A1 338/4885
US-12486240-B2 Oxadiazole compounds for controlling or preventing phytopathogenic fungi OXA1L, CYP51A1, ERG28 HDAC1 939/4885HDAC6 1436/4885ALDH1A1 400/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 HDAC1 1659/4885HDAC6 50/4885ALDH1A1 656/4885
US-20240400546-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 HDAC1 1659/4885HDAC6 50/4885ALDH1A1 656/4885
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 HDAC1 1659/4885HDAC6 50/4885ALDH1A1 656/4885
US-20250179084-A1 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS HIPK2, HIPK3, HIPK1 HDAC1 430/4885HDAC6 790/4885ALDH1A1 2264/4885
US-20050113400-A1 Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo SP1, AP1G1, JUN HDAC1 49/4885HDAC6 1044/4885ALDH1A1 1493/4885
US-11970486-B2 Compounds and uses thereof NLN, ACHE, CLN6 HDAC1 1659/4885HDAC6 50/4885ALDH1A1 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.